Physiomics Share Discussion Threads

[spacedust] 17/4/2018 14:07

There's nothing wrong with that. I've given up on aim after over a decade in making losses. Now on ftse 250 and 100 companies and have made decent returns last couple of years. Excellent decision ....bit boring but profit is not boring.

Not investing in milking cows no more. Once thus bag of shi7e has broken even and sareum that's me done with aim

[festario] 17/4/2018 13:32

Stigologist, I assume that your silence means that you gave up on VRS, and sold up?

[spacedust] 17/4/2018 11:59

A bit of an anti climax today

[the stigologist] 17/4/2018 11:08

indeed

Merck a clear leader in immune-oncology

[multibagger123] 17/4/2018 10:12

Interesting...Merck lung cancer trial boosts immunotherapy hopeshttps://www.ft.com/content/fb268fe6-40c9-11e8-803a-295c97e6fd0b

[tmmalik] 17/4/2018 07:41

Another thrilling day expectedLet see if we can cross 7.50 today

[the stigologist] 16/4/2018 22:47

@Stockonomist
Replying to @Jarvy55

#PYC Charts looking interesting going into next weeks Conference and more potential newsflow

[the stigologist] 16/4/2018 21:23

The AACR and the UBS Oncology Impact Fund Managed by MPM Capital Announce First Funding Gift to Fuel Innovation to Propel Breakthroughs Against Cancer

4/16/2018

​CHICAGO – The American Association for Cancer Research (AACR) and the UBS Oncology Impact Fund (OIF) managed by MPM Capital are extremely proud to announce the first funding gift to the joint AACR-MPM Transformative Cancer Research Grants Program* in support of innovative research that will accelerate breakthroughs against cancer. The first contribution from the fund to AACR – a total of US$1.2 million – was announced at the AACR Annual Meeting 2018, April 14–18. The fund is also due to donate a second US$1.2 million to UBS's Optimus Foundation to support emerging market access to cancer care, or US$2.5 million in total.

“Cancer is the second leading cause of death globally, and much more research is urgently needed if we are to markedly reduce the incidence, morbidity, and mortality of this devastating disease. The AACR is deeply grateful to UBS and MPM Capital for their extraordinary commitment to this partnership, as this funding will help further ignite high-impact, transformative research that will catalyze advances in cancer research, result in the development of novel products and have a significant impact on future clinical practice,” said Margaret Foti, PhD, MD (hc), Chief Executive Officer of the AACR.

The OIF is a first-of-its-kind social impact fund dedicated to investing in oncology therapeutics. The fund was structured and raised by UBS and is managed by MPM. With US$471 million at its close in April 2016, the fund invests across a spectrum of companies, from early-stage start-ups through public companies. These companies are developing transformative cancer therapeutics that aim to have a significant impact on improvements in patient outcomes and well-being

[the stigologist] 16/4/2018 20:32

Interesting list of sponsors

Glaxo
Lilly
Sanofi
Novo Nordisk
Bristol Myers Squibb
Johnson & Johnson Innovation
and our Government friends and sponsors Innovate UK

[myamay16] 16/4/2018 20:20

Jim has got a 5 min slot for company update on 24th.

hxxps://www.biotrinity.com/sites/default/files/BioLaunchPad%20Programme%20v4%209April2018.pdf

[bobdown2] 16/4/2018 20:08

Stigologist.....a very good post. Maybe there is something really good lurking in the background.

[spacedust] 16/4/2018 19:52

Good spot Stig.

[the stigologist] 16/4/2018 18:51

Whilst quite rightly next week's Conference presentation and 'Company Update' has excited the share price today I think it's worth pointing out Physiomics are still at the ongoing AACR #AACR #AACR18 Conference in the United States where they are presenting their 'Late Breaking Abstract' on their Personalised Cancer Care Decision Support System tool. ( )

Think it's worth drawing peoples attention to what you need to show the experts at AACR that your Abstract is worthy of presentation and publication at their conference.

From the AACR website :-



Abstracts detailing highly significant and timely findings in any area of cancer research that were not available at the time of the regular abstract deadline may be submitted for consideration as a late-breaking abstract. Only those abstracts that are deemed to be of high scientific priority will be accepted.

Now why would the Conference organisers deem Physiomics abstract to meet the above requirements ? Which of the 'great and good' who attend AACR will now be beating a path to Physiomics door to partner and further develop their technology ?

Let's just say it might not just be multi-billion Pharmaceutical companies wanting to partner with PYC on th

[spacedust] 16/4/2018 17:58

Best outcome would be 29% rise everyday until rns

[margic] 16/4/2018 17:16

Just perfectly poised. This has been brewing for weeks. Hope this pop pop blows!

[the stigologist] 16/4/2018 17:10

@Stockonomist

Can see why #PYC Physiomics planning their Corporate Update for April 24th 2018 at #BioTrinity #BioTrinity2018

[festario] 16/4/2018 16:28

Stigologist, have you given up on VRS now?

[spacedust] 16/4/2018 16:09

We need a 300k buy. Plus if JC goes for 1m buy or 2x500k buys then we may well see 14p. Price needs to end strongly today into 9p for sustained rises tomorrow

[spacedust] 16/4/2018 16:01

13p finish???!!!